A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
It is commonly suggested by scholars that the EPRDF's decision to establish a federal administrative structure along ethnic lines was a move towards reinforcing its political dominance. By dividing the country and facilitating the creation of accompanying ethnically-based parties under the government's control, the TPLF (which represented less than 10% of the country's population) could intensify its hold on power. Dissatisfied opposition parties argued that this form of federalization was not appropriate for the country. For instance, the All Amhara People's Organisation (AAPO) and the Ethiopian Democratic Union Party expressed in 2000 that they preferred a strong unitary state with representation of the country's nationalities at the core. Other groups, such as the Oromo National Congress (ONC) and the Ethiopia Democratic Party (EDP), were not opposed to the idea of establishing a federal system, arguing that it set the foundation for regional autonomy, but believed that it was a mistake for it to conducted along ethnic lines.
Se8 + 24 F2 → 8 SeF6 In comparison with its sulfur counterpart (sulfur hexafluoride), selenium hexafluoride (SeF6) is more reactive and is a toxic pulmonary irritant. Selenium tetrafluoride is a laboratory-scale fluorinating agent. The only stable chlorides are selenium tetrachloride (SeCl4) and selenium monochloride (Se2Cl2), which might be better known as selenium(I) chloride and is structurally analogous to disulfur dichloride. Metastable solutions of selenium dichloride can be prepared from sulfuryl chloride and selenium (reaction of the elements generates the tetrachloride instead), and constitute an important reagent in the preparation of selenium compounds (e.g. Se7). The corresponding bromides are all known, and recapitulate the same stability and structure as the chlorides. The iodides of selenium are not well known, and for a long time were believed not to exist. There is limited spectroscopic evidence that the lower iodides may form in bi-elemental solutions with nonpolar solvents, such as carbon disulfide and carbon tetrachloride; but even these appear to decompose under illumination. Some selenium oxyhalides—seleninyl fluoride (SeOF2) and selenium oxychloride (SeOCl2)—have been used as specialty solvents.
=== Small RNA molecules regulate gene expression by post-transcriptional gene silencing === Another previously unknown mechanism by which RNA molecules are involved in genetic regulation was discovered in the 1990s. Small RNA molecules termed microRNA (miRNA) and small interfering RNA (siRNA) are abundant in eukaryotic cells and exert post-transcriptional control over mRNA expression. They function by binding to specific sites within the mRNA and inducing cleavage of the mRNA via a specific silencing-associated RNA degradation pathway.
Sources: en.wikipedia.org
Spark ionization (also known as spark source ionization) is a method used to produce gas phase ions from a solid sample. The prepared solid sample is vaporized and partially ionized by an intermittent discharge or spark. This technique is primarily used in the field of mass spectrometry. When incorporated with a mass spectrometer the complete instrument is referred to as a spark ionization mass spectrometer or as a spark source mass spectrometer (SSMS).
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016.
Portal 2 development was restarted specifically to keep the portal concept but adding new elements to freshen the gameplay. During this period, Valve had witnessed another student project out of DigiPen, Tag: The Power of Paint, which allows the player to spray paint onto surfaces to alter their behavior. The team was brought into Valve, though not initially as part of the Portal franchise. The Tag team had found a way to incorporate their paints with real-time fluid dynamics code previously made by Valve, and the concept became the "conversion gels" found in Portal 2. Valve included a co-operative play mode, based on their own observations and stories from players about working out the solutions to Portal's puzzles in a group environment. With this feature, they sought the ability to enable cross-platform play of Portal 2 between computers and consoles through Steamworks. This led to a surprise reveal by Newell that Portal 2 would be released on the PlayStation 3, despite previously expressing how he felt about the difficulties in supporting the console, and that it would include support for cross-platform play between the PC and PS3 versions through a limited Steamworks interface. Valve brought in writer Jay Pinkerton, who had formerly worked on National Lampoon, as well as Left 4 Dead writer Chet Faliszek to assist Wolpaw with the larger story.
== Congresses == I National Congress – Prato, 1 March 1998 II National Congress – Trieste, 10 October 1999 III National Congress – Torino, 2 December 2001 IV National Congress – Torino, 29 October 2006 V National Congress – Villanova d'Asti, 6 November 2011 VI Congresso Nazionale - Villanova d'Asti, 30 ottobre 2016 VII Congresso Nazionale - San Paolo Solbrito, 5 giugno 2022
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.